［1］Ferlay J，Soerjomataram I，Dikshit R，et al．Cancer incidence and mortality worldwide：Sources，methods and major patterns in Globocan 2012［J］.Int J Cancer，2015，136(5)：E359-386.
[2]SUN ML，XU JY.Stereotactic radiotherapy for early stage of non-small cell lung cancer［J］.Practical Oncology，2018，32(1)：53-56.［孙明亮，徐建宇.早期非小细胞肺癌立体定向放疗的相关研究［J］.实用肿瘤学杂志，2018，32(1)：53-56.］
[3]FANG F，JU XP，ZHANG HJ，et al.Cyberknife radiosurgery treatment of peripheral non-small cell lung cancer：Clinical analysis［J］.Academic Journal of Second Military Medical University，2016，37(01)：98-101.［方芳，居小萍，张火俊，等.射波刀治疗周围型非小细胞肺癌临床分析［J］.第二军医大学学报，2016，37(01)：98-101.］
[4]MENG LL，DI YP，DU LH，et al.Observation on curative effect of SBRT and QOL of treated elder patient with early NSCLC［J］.China Medical Equipment，2018，15(7)：27-32.［孟玲玲，邸玉鹏，杜乐辉，等.老年早期非小细胞肺癌立体定向放射治疗的疗效及生活质量观察［J］.中国医学装备，2018，15(7)：27-32.］
[5]YU X，WANG YM.Cyberknife treatment for non-small cell lung cancer［J］.J Int Oncol，2014，41(2)：107-109.［于霄，汪延明.射波刀在治疗非小细胞肺癌中的临床应用［J］.国际肿瘤学杂志，2014，41(2)：107-109.］
[6]BAI WJ.Thoracoscopic surgery for early-stage non-small cell lung cancer practical clinical medicine［J］.Practical Clinical Medicine，2016，17(07)：33-35.［白文杰.胸腔镜手术治疗早期非小细胞肺癌的临床疗效［J］.实用临床医学，2016，17(07)：33-35.］
[7]Kuremsky JG，Urbanic JJ，Pecty WJ，et al．Tumor histology predicts patterns of failure and survival in patients with brain metastases from lung cancer treated with gamma knife radiosurgery［J］．Neurosurgery，2013，73(4)：641-647.
[8]ZHANG JX，HAO CC，LUO JN，et al.Stereotactic radiotherapy for early stage non-small cell lung cancer［J］.Modern Oncology，2016，24(16)：2644-2647.［张建鑫，郝春成，罗佳宁，等.早期非小细胞肺癌的体部立体定向放射治疗进展［J］.现代肿瘤医学，2016，24(16)：2644-2647.］
[9]Chang JY，Senan S，Paul MA，et al.Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer：A pooled analysis of two randomized trials［J］.Lancet Oncol，2015，16(6)：630-637.
[10]Sun B，Brooks ED，Komaki RU，et al.7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer：Results of a phase 2 clinical trial［J］.Cancer，2017，123(16)：3031-3039.
[11]Chi A，Liao Z，Nguyen NP，et al.Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer：Clinical implications［J］.Radiother Oncol，2010(94)：1-11.
[12]Shultz DB，Trakul N，Abelson JA，et al.Imaging features associated with disease progression after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer［J］.Clin Lung Cancer，2014(15)：294-301.
[13]De Ruysscher D.18F-deoxyglucose uptake in stage I non-small-cell lung cancer：Time to move to randomized trials［J］.J Thorac Oncol，2014，9(1)：5-6.
[14]Lischalk JW，Woo SM，Kataria S，et al.Long-term outcomes of stereotactic body radiation therapy with fiducial tracking for in operable stage I non-small cell lung cancer［J］.J Radiat Oncol，2016，5(4)：379-387.
[15]Takeda A，Sanuki N，Kunieda E，et al．Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm［J］．Int J Radiat Oncol Biol Phys，2009，73(2)：442-448.
[16]Jeppesen SS，Schytte T，Jensen HR，et al．Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer：An updated retrospective study on local failure and survival rates［J］．Acta Oneologica，2013，52(7)：1552-1558.
[17]Takeda A,Ohashi T,Kunieda E,et al.Comparison of clinical, tumour-related and dosimetric factors in grade 0-1, grade 2 and grade 3 radiation pneumonitis after stereotactic body radiotherapy for lung tumours［J］.Br J Radiol,2012(85):636-642.